This review focuses on the therapeutic application of Tocilizumab (TCZ) in the treatment of
COVID-19, specifically exploring its mechanisms, safety aspects, clinical efficacy, dosing …

BACKGROUND The majority of patients with coronavirus disease 2019 (COVID-19) have
good prognoses, but some develop a critical illness that can lead to death. Evidence shows …

Background Selection of effective and safe therapy for management of patients with
coronavirus disease is challenging. Tocilizumab (TZB) has emerged as a potential treatment …

Introduction The results of studies of tocilizumab (TCZ) in COVID‐19 are contradictory. Our
study aims to update medical evidence from controlled observational studies and …

Background This systematic review and meta-analysis was aimed to evaluate the efficacy
and safety of tocilizumab (TCZ) in treating severe coronavirus disease 2019 (COVID-19) …

Background Interleukin-6 inhibitors showed promising results in observational trials of
patients with coronavirus disease 2019 (COVID-19). Aim To evaluate whether interleukin-6 …

Background: Among the several therapeutic options assessed for the treatment of
coronavirus disease 2019 (COVID-19), tocilizumab (TCZ), an antagonist of the interleukine …

Introduction: there is evidence on the effectiveness and safety of tocilizumab (TZC) used in
combination with systemic corticosteroids for severe SARS-CoV-2 pneumonia treatment …

Tocilizumab is a competitive interleukin-6 inhibitor agent that has been proposed to combat
the COVID-19-related hyperinflammatory state, known as a cytokine storm. This systematic …

Objective: This study aimed to assess the role of Tocilizumab therapy (TCZ) in terms of ICU
admission and mortality rate of critically ill patients with severe COVID-19 pneumonia …